In addition, a recent study revealed that visfatin also acts as an inhibitor of the 5-fluorouracil (5-FU) therapeutic effect in CRC patients through visfatin/SDF-1/Akt pathway activation (Table 1) [80]. The gene discussed is AKT1; the disease is colorectal carcinoma.